JPMorgan Chase & Co. Purchases 13,420 Shares of Savara Inc (NASDAQ:SVRA)

JPMorgan Chase & Co. boosted its position in shares of Savara Inc (NASDAQ:SVRA) by 23.9% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 69,490 shares of the company’s stock after acquiring an additional 13,420 shares during the period. JPMorgan Chase & Co.’s holdings in Savara were worth $295,000 at the end of the most recent quarter.

A number of other hedge funds also recently bought and sold shares of SVRA. Wellington Management Group LLP lifted its position in shares of Savara by 22.9% during the 3rd quarter. Wellington Management Group LLP now owns 8,624,012 shares of the company’s stock worth $36,566,000 after purchasing an additional 1,608,522 shares during the last quarter. Vestal Point Capital LP lifted its holdings in shares of Savara by 24.7% during the third quarter. Vestal Point Capital LP now owns 8,090,000 shares of the company’s stock worth $34,302,000 after buying an additional 1,600,000 shares during the last quarter. Jennison Associates LLC boosted its position in shares of Savara by 17.5% in the third quarter. Jennison Associates LLC now owns 6,732,776 shares of the company’s stock valued at $28,547,000 after acquiring an additional 1,001,296 shares during the period. State Street Corp grew its stake in shares of Savara by 15.7% in the third quarter. State Street Corp now owns 4,138,276 shares of the company’s stock worth $17,546,000 after acquiring an additional 560,242 shares during the last quarter. Finally, Geode Capital Management LLC increased its position in Savara by 10.8% during the third quarter. Geode Capital Management LLC now owns 2,726,850 shares of the company’s stock worth $11,564,000 after acquiring an additional 264,825 shares during the period. 87.93% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other Savara news, Director Joseph S. Mccracken bought 20,000 shares of the firm’s stock in a transaction dated Tuesday, November 19th. The shares were bought at an average price of $2.95 per share, for a total transaction of $59,000.00. Following the completion of the acquisition, the director now owns 210,837 shares of the company’s stock, valued at approximately $621,969.15. This trade represents a 10.48 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Matthew Pauls sold 54,702 shares of Savara stock in a transaction dated Monday, December 16th. The shares were sold at an average price of $3.31, for a total value of $181,063.62. Following the completion of the transaction, the chief executive officer now directly owns 1,536,379 shares of the company’s stock, valued at $5,085,414.49. This represents a 3.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 5.13% of the company’s stock.

Savara Price Performance

Shares of SVRA stock opened at $2.80 on Friday. The stock’s fifty day simple moving average is $3.15 and its 200 day simple moving average is $3.75. Savara Inc has a one year low of $2.59 and a one year high of $5.70. The firm has a market cap of $480.54 million, a price-to-earnings ratio of -6.51 and a beta of 0.68. The company has a debt-to-equity ratio of 0.13, a current ratio of 17.70 and a quick ratio of 17.70.

Savara (NASDAQ:SVRA) last issued its earnings results on Tuesday, November 12th. The company reported ($0.11) EPS for the quarter, meeting the consensus estimate of ($0.11). On average, analysts expect that Savara Inc will post -0.45 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on SVRA shares. HC Wainwright cut their price objective on shares of Savara from $10.00 to $6.00 and set a “buy” rating for the company in a research report on Wednesday, November 13th. Evercore ISI restated an “in-line” rating and set a $5.00 price objective (down from $7.00) on shares of Savara in a research report on Wednesday, November 13th. JMP Securities restated a “market outperform” rating and issued a $9.00 target price on shares of Savara in a research note on Thursday, December 19th. Finally, Wells Fargo & Company began coverage on shares of Savara in a research note on Friday, December 20th. They set an “overweight” rating and a $8.00 price target on the stock. One research analyst has rated the stock with a hold rating and six have given a buy rating to the company. Based on data from MarketBeat, Savara has an average rating of “Moderate Buy” and a consensus price target of $9.86.

Savara Company Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.